The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Y-Mabs Therapeutics Inc shares valued at $192,928 were purchased by Ber Gerard on Sep 03 ’24. At $13.83 per share, Ber Gerard acquired 13,950 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Lund-Hansen Torben sold 50,000 shares, netting a total of over 768,500 in proceeds. Following the sale of shares at $15.37 each, the insider now holds 35,600 shares.
Before that, Lund-Hansen Torben had added 50,000 shares to its account. In a trade valued at $768,432, the Officer bought Y-Mabs Therapeutics Inc shares for $15.37 each.
As published in their initiating research note from Cantor Fitzgerald on August 16, 2024, Y-Mabs Therapeutics Inc [YMAB] has been an Overweight and the price target has been revised to $20. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. As of May 10, 2023, Wedbush has increased its “Neutral” rating to a “an Outperform” for YMAB. Earlier on April 03, 2023, Guggenheim downgraded its rating. Their new recommendation was “a Neutral” for YMAB stock which previously was a “a Buy”.
Analyzing YMAB Stock Performance
During the last five days, there has been a drop of approximately -5.34%. Over the course of the year, Y-Mabs Therapeutics Inc shares have jumped approximately 110.56%. Shares of the company reached a 52-week high of $20.90 on 03/01/24 and a 52-week low of $6.48 on 01/03/24. A 50-day SMA is recorded $12.37, while a 200-day SMA reached $12.16. Nevertheless, trading volume fell to 0.31 million shares from 0.4 million shares the previous day.
Support And Resistance Levels for Y-Mabs Therapeutics Inc (YMAB)
According to the 24-hour chart, there is a support level at 13.69, which, if violated, would cause prices to drop to 13.03. In the upper region, resistance lies at 14.76. The next price resistance is at 15.17. RSI (Relative Strength Index) is 59.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.35, which suggests the price will decrease in the coming days. Percent R is at 34.31%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
